NCT07195734 2026-04-13
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
18 trialsNCT06317311 2025-07-25
RUBY-J
GlaxoSmithKline
Phase 2 Active not recruiting
NCT06084845 2024-07-25
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT02412670 2023-07-10
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00176267 2023-06-01
Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer
University of Kentucky
Phase 2 Completed
NCT00176254 2023-05-16
Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer
University of Kentucky
Phase 2 Completed
NCT00152477 2022-04-12
A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
UCB Pharma
Phase 2 Completed
NCT03128008 2021-05-28
ADAPT
Duke University
Phase 2 Completed
NCT02392507 2020-11-19
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Eli Lilly and Company
Phase 2 Completed
NCT02259582 2020-09-09
DENALI
Mereo BioPharma
Phase 2 Completed
NCT01063075 2019-09-26
A Study in Advanced Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT01218048 2018-08-16
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
Phase 2 Completed
NCT00226590 2017-03-23
Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00737243 2016-08-17
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00998192 2016-03-31
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Oncolytics Biotech
Phase 2 Completed
NCT00861627 2015-12-02
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Oncolytics Biotech
Phase 2 Completed
NCT00753038 2014-11-04
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
Oncolytics Biotech
Phase 2 Completed
NCT00034346 2007-12-24
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Amgen
Phase 2 Completed